Future antidepressants: what is in the pipeline and what is missing?
Monoamine reuptake inhibitors still reign in the treatment of major depression, but possibly not for long. While medicinal chemists have been able to reduce the side effects of these drugs, their delayed onset of action and considerable non-response rate remain problematic. Of late, serious questions have been raised regarding the efficacy of monoamine reuptake inhibitors. The present review presents an inventory of what is (and until recently was) in the antidepressant pipeline of pharmaceutical companies. Novel antidepressant compounds can be categorised into four groups depending on their target(s): (i) monoamine receptors; (ii) non-monoamine receptors; (iii) neuropeptide receptors; and (iv) hormone receptors. Other possible targets include components of post-receptor intracellular processes and elements of the immune system; to date, however, compounds specifically aimed at these targets have not been the subject of clinical trials. Development of several compounds targeted at monoamine receptors has recently been discontinued. At least five neurokinin-1 (NK(1)) receptor antagonists were until recently in phase II of clinical testing. However, the apparent interest in the NK(1) receptor should not be interpreted as representing a departure from the monoamine hypothesis since neurokinins also modulate monoaminergic systems. In the authors' view, development of future antidepressants will continue to rely on the serendipity-based monoamine hypothesis. However, an alternative approach, based on the hypothesis that chronic stress precipitates depressive symptoms, might be more productive. Unfortunately, clinical results using drugs targeted at components of the HPA axis have not been very encouraging to date. In the short run, the authors believe that augmentation strategies offer the best hope for improving the efficacy of antidepressant treatment. Several approaches to improve the efficacy of SSRIs are conceivable, such as concurrent blockade of monoamine autoreceptors and the addition of antipsychotics, neuromodulators or hormones (HPA axis and gender related). In the long-term, however, construction of a scientifically verified conceptual framework will be needed before more effective antidepressants can be developed. It can be argued that it is not depression itself that should be treated, but rather that its duration should be reduced by pharmacological means. Animal models that take this concept into consideration and identify mechanisms for acceleration of recovery from the effects of stress need to be developed.
Bosker
Fokko J
FJ
Department of Psychiatry, University and University Hospital of Groningen, Hanzeplein 1, PO Box 30 001, Groningen, 9700 RB, The Netherlands. f.j.bosker@acggn.azg.nl
Westerink
Ben H C
BH
Cremers
Thomas I F H
TI
Gerrits
Marjolein
M
van der Hart
Marieke G C
MG
Kuipers
Sjoukje D
SD
van der Pompe
Gieta
G
ter Horst
Gert J
GJ
den Boer
Johan A
JA
Korf
Jakob
J
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use*; D015306:Biogenic Monoamines / Q000627:therapeutic use; D016207:Cytokines / Q000737:chemistry / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D005544:Forecasting; D006728:Hormones / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D009479:Neuropeptides / Q000737:chemistry / Q000627:therapeutic use; D011956:Receptors, Cell Surface / Q000145:classification / Q000502:physiology
D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents; D015306:Biogenic Monoamines; D016207:Cytokines; D006728:Hormones; D009479:Neuropeptides; D011956:Receptors, Cell Surface